{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"}],"units":"Participants"}],"description":"Feasibility failure is defined as a) interventional radiologist is unable to access the ophthalmic artery for the 1st chemotherapy administration for any reason; b) patient develops central retinal artery occlusion after the 1st or 2nd course that does not reopen by the time the next injection is due; or c) the patient cannot receive all three treatments because of Common Terminology Criteria for Adverse Events (CTCAE) complications grade III or IV that are considered possibly, probably or likely related treatment.","groups":[{"description":"Patients receive melphalan intra-arterial (IA) on day 1. Treatment repeats every 28 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.\n\nMelphalan: Given IA","id":"OG000","title":"Melphalan"}],"paramType":"NUMBER","populationDescription":"All Patients who are eligible and evaluable for the feasibility outcome are included in this outcome","reportingStatus":"POSTED","timeFrame":"Up to 4 months","title":"Number of Patients Experiencing Feasibility Failure","type":"PRIMARY","unitOfMeasure":"participants"}